PMPooja Mittal

Pooja Mittal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pooja Mittal has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Sonia S. Hassan

    Department of Physiology, Wayne State University School of Medicine, Detroit, MI; Office of Women's Health, Wayne State University, Detroit, MI

    7 shared publications
  • Juan Pedro Kusanovic

    Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland, and Detroit, Michigan, USA

    6 shared publications
  • Roberto Romero

    Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, United States Department of Health and Human Services, Bethesda, MD; Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI; Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

    6 shared publications
  • Heinz-Josef Lenz

    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA

    5 shared publications
  • Indrakant Kumar Singh

    Molecular Biology Research Lab, Department of Zoology, Deshbandhu College, University of Delhi, Kalkaji, New Delhi, 110019, India.

    5 shared publications
  • Lami Yeo

    Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD and Detroit, MI, USA

    5 shared publications

Latest Publications

  • Role of Monoamine Oxidases in Colorectal cancer: Prognostic implications and therapeutic potential of MAOA and MAOB

    by Shradheya R. R. Gupta, Vanshika Rustagi, Shivani Singh, Nancy Sanjay Gupta, Pooja Mittal, Shivani Soni, Heinz-Josef Lenz, Indrakant K. Singh

    Monoamine oxidases (MAOs) are mitochondrial enzymes that degrade monoamines released by neurons and glial cells, thereby regulating cellular signalling and redox balance. Increasing evidence indicates that the two isoforms, MAOA and MAOB, play complex and context-dependent roles in cancer biology, including colorectal cancer (CRC). This review summarizes and critically evaluates current literature and available data on the expression patterns, prognostic significance, and functional roles of MAOA and MAOB in CRC, and contrasts these findings with observations reported in other cancer types. Available studies consistently indicate that reduced MAOA expression in CRC is associated with poor patient prognosis, suggesting a potential protective role of MAOA through modulation of oxidative stress and regulation of oncogenic pathways such as EGFR transactivation. In contrast, elevated MAOA expression has been linked to poor survival outcomes in several other malignancies, underscoring strong cancer-type specificity. MAOB expression in CRC is generally low; however, higher MAOB levels have been associated with worse survival, potentially reflecting tumour heterogeneity, microenvironmental influences, or stage-dependent expression. Collectively, these contrasting patterns highlight the biological complexity and context-dependent functions of MAOs in cancer. The review emphasizes the need for larger, well-characterized clinical cohorts and mechanistic studies to clarify the translational potential of MAOA and MAOB as prognostic biomarkers or therapeutic targets in CRC.

  • Canonical and non-canonical intricacies of MCL-1 in cancer

    by Pooja Mittal, Heinz-Josef Lenz


  • Open Access

    Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer

    by Pooja Mittal, Francesca Battaglin, Yan Yang, Shivani Soni, Sebastian Stintzing, Aparna R. Parikh, Karam Ashouri, Sandra Algaze, Priya Jayachandran, Lesly Torres-Gonzalez, et al.

    The immune system is alerted for virally infected cells in the body by the antigen presentation pathway, which is in turn mediated by the major histocompatibility complex (MHC) class I and II molecules. Cancer cells overcome immune evasion as a major hallmark by downregulation of the antigen presentation pathway. Therefore, the present study aimed to explore the effect of genetic variants in genes involved in MHC class I and II pathways in patients treated with first-line chemotherapy in combination with targeted antibodies in metastatic colorectal cancer (mCRC) patients. Genomic DNA from the blood samples of 775 patients enrolled in three independent, randomized, first-line trials, namely TRIBE (FOLFIRI-bevacizumab, N = 215), FIRE-3 (FOLFIRI-bevacizumab, N = 107; FOLFIRI-cetuximab, N = 129), and MAVERICC (FOLFIRI-bevacizumab, N = 163; FOLFOX6-bevacizumab, N = 161), was genotyped through OncoArray, a custom array manufactured by Illumina including approximately 530K SNP markers. The impact on the outcome of 40 selected SNPs in 22 genes of MHC class I and II pathways was analyzed. We identified several SNPs in multiple genes associated with targeted treatment benefits across different treatment arms in our study population (p < 0.05). Treatment–SNP interaction analyses confirmed a significant treatment interaction with the targeted agents (bevacizumab vs. cetuximab) and the chemotherapy backbone (FOLFIRI vs. FOLFOX) in certain selected SNPs. Our results highlight a potential role for MHC SNPs as prognostic and predictive biomarkers for first-line treatment in mCRC, with differential effects based on the biologic agent and chemotherapy backbone. These biomarkers, when further validated, may contribute to personalized treatment strategies for mCRC patients.


  • Open Access

    Comprehensive characterization of MCL‐1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes

    by Pooja Mittal, Francesca Battaglin, Yasmine Baca, Joanne Xiu, Alex Farrell, Shivani Soni, Jae Ho Lo, Lesly Torres‐Gonzalez, Sandra Algaze, Priya Jayachandran, et al.

    Myeloid cell leukemia 1 (MCL‐1) is a member of the B‐cell lymphoma 2 protein family and has anti‐apoptotic functions. Deregulation of MCL‐1 has been reported in several cancers, including lung and breast cancer. In the present study, the association of MCL‐1 expression with molecular features in colorectal cancer (CRC) has been highlighted. CRC samples from Caris Life Sciences (Phoenix, AZ) were analyzed using NextGen DNA sequencing, whole transcriptome sequencing, whole exome sequencing, and immunohistochemistry (IHC); and stratified based on MCL‐1 expression as top quartile MCL‐1high (Q4) and bottom quartile MCL‐1low (Q1). Immune cell infiltration (CI) in the tumor microenvironment (TME) was measured using RNA deconvolution analysis (QuanTIseq). MCL‐1high tumors were associated with an increased rate of programmed death ligand 1 IHC, higher T cell‐inflamed signature, interferon score, microsatellite instability‐high and tumor mutational burden‐high status. MCL‐1high was associated with higher mutation rates of BCOR, TP53, KMT2D, ASXL1, KDM6A, ATM, MSH6, SPEN, KRAS, STK11, GNAS, RNF43, and lower mutation rates of CDKN1B, NRAS, and APC, and copy number amplifications in several genes. MCL‐1high TME had higher CI of M1 and M2 macrophages, B cells, natural killer cells, neutrophils, and T‐regulatory cells infiltration, and lower CI of myeloid dendritic cells. Higher MCL‐1 expression is significantly associated with favorable clinical outcomes in CRC cohorts. Our data showed a strong correlation between MCL‐1 and distinct immune biomarkers and TME CI in CRC. Our findings suggest MCL‐1 is a potential modulator of antitumor immunity, TME, and biomarker in CRC.


  • Open Access

    Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review

    by Karam Ashouri, Alexandra Wong, Pooja Mittal, Lesly Torres-Gonzalez, Jae Ho Lo, Shivani Soni, Sandra Algaze, Taline Khoukaz, Wu Zhang, Yan Yang, et al.

    Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors have significantly improved patient outcomes, their effectiveness is mostly limited to tumors with microsatellite instability (MSI-H/dMMR) or an increased tumor mutational burden, which comprise 10% of cases. Advancing personalized medicine in CRC hinges on identifying predictive biomarkers to guide treatment decisions. This comprehensive review examines established tissue markers such as KRAS and HER2, highlighting their roles in resistance to anti-EGFR agents and discussing advances in targeted therapies for these markers. Additionally, this review summarizes encouraging data on promising therapeutic targets and highlights the clinical utility of liquid biopsies. By synthesizing current evidence and identifying knowledge gaps, this review provides clinicians and researchers with a contemporary understanding of the biomarker landscape in CRC. Finally, the review examines future directions and challenges in translating promising biomarkers into clinical practice, with the goal of enhancing personalized medicine approaches for colorectal cancer patients.


  • Silibinin: an inhibitor for a high-expressed BCL-2A1/BFL1 protein, linked with poor prognosis in breast cancer

    by Shradheya R. R. Gupta, Pooja Mittal, Bishwajit Kundu, Archana Singh, Indrakant K. Singh

    Breast cancer (BC) accounts for 30% of all diagnosed cases of cancer in women and remains a leading cause of cancer-related deaths among women worldwide. The current study looks for a protein from the anti-apoptotic/pro-survival BCL-2 family whose overexpression reduces survivability in BC patients and a potential inhibitor for the protein. We found BCL-2A1/BFL1 protein with high expression linked to low survivability in BC. The protein shows prognosis in 8 out of 29 categories, whereas no other family member manifests this property. Out of 7379 compounds, three small molecules (CHEMBL9509, CHEMBL2104550 and CHEMBL3545011) form an H-bond with BCL-2A1/BFL1 protein's unique residue Cys55. Of the three small molecules, we found CHEMBL9509 (Silibinin) to be a potent inhibitor. The compound forms a stable H-bond with the residue Cys55 with the lowest binding energy compared to the other two compounds. It remains stable in the BH3 binding region for more than 100 ns, whereas the other two detach from the region. Additionally, the compound is found to be better than Venetoclax and Nematoclax. We firmly believe in the compound CHEMBL9509 potency to halt BC's progression by inhibiting the BCL-2A1/BFL1 protein, increasing patients' survivability.Communicated by Ramaswamy H. Sarma.


  • Open Access

    A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

    by Tinnakorn Chaiworapongsa, Roberto Romero, Adi L. Tarca, Juan Pedro Kusanovic, Francesca Gotsch, Pooja Mittal, Sun Kwon Kim, Edi Vaisbuch, Shali Mazaki-Tovi, Offer Erez, et al.


  • Open Access

    Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid

    by Tinnakorn Chaiworapongsa, Roberto Romero, Juan P. Kusanovic, Zeynep A. Savasan, Sun Kwon Kim, Shali Mazaki-Tovi, Edi Vaisbuch, Giovanna Ogge, Ichchha Madan, Zhong Dong, et al.

    Objective. Angiogenesis is critical for successful pregnancy. An anti-angiogenic state has been implicated in preeclampsia, fetal growth restriction and fetal death. Increased maternal plasma concentrations of the anti-angiogenic factor, soluble vascular endothelial growth factor receptor (sVEGFR)-1, have been reported in women with preeclampsia and in those with fetal death. Recent observations indicate that an excess of sVEGFR-1 and soluble endoglin (sEng) is also present in the amniotic fluid of patients with preeclampsia. The aim of this study was to determine whether fetal death is associated with changes in amniotic fluid concentrations of sVEGFR-1 and sEng, two powerful anti-angiogenic factors. Study design. This cross-sectional study included patients with fetal death (n = 35) and controls (n = 129). Fetal death was subdivided according to clinical circumstances into: (1) unexplained (n = 25); (2) preeclampsia and/or placental abruption (n = 5); and (3) chromosomal/congenital anomalies (n = 5). The control group consisted of patients with preterm labor (PTL) who delivered at term (n = 92) and women at term not in labor (n = 37). AF concentrations of sVEGFR-1 and sEng were determined by ELISA. Non-parametric statistics and logistic regression analysis were applied. Results. (1) Patients with a fetal death had higher median amniotic fluid concentrations of sVEGFR-1 and sEng than women in the control group (p < 0.001 for each); (2) these results remained significant among different subgroups of stillbirth (p < 0.05 for each); and (3) amniotic fluid concentrations of sVEGFR-1 and those of sEng above the third quartile were associated with a significant risk of unexplained preterm fetal death (adjusted OR = 10.8; 95%CI 1.3–89.2 and adjusted OR 87; 95% CI 2.3–3323, respectively). Conclusion. Patients with an unexplained fetal death at diagnosis are characterized by an increase in the amniotic fluid concentrations of sVEGFR-1 and sEng. These observations indicate that an excess of anti-angiogenic factors in the amniotic cavity is associated with unexplained fetal death especially in preterm gestations.


  • Open Access

    Pentraxin 3 in maternal circulation: An association with preterm labor and preterm PROM, but not with intra-amniotic infection/inflammation

    by Laura Cruciani, Roberto Romero, Edi Vaisbuch, Juan Pedro Kusanovic, Tinnakorn Chaiworapongsa, Shali Mazaki-Tovi, Zhong Dong, Sun Kwon Kim, Giovanna Ogge, Lami Yeo, et al.

    Objective. Pentraxin 3 (PTX3) is an acute-phase protein that has an important role in the regulation of the innate immune response. The aim of this study was to determine if maternal plasma PTX3 concentration changes in the presence of intra-amniotic infection and/or inflammation (IAI) in women with preterm labor (PTL) and intact membranes, as well as those with preterm prelabor rupture of membranes (preterm PROM). Study design. This cross-sectional study included women in the following groups: (1) nonpregnant (n = 40); (2) uncomplicated pregnancies in the first (n = 22), second (n = 22) or third trimester (n = 71, including 50 women at term not in labor); (3) uncomplicated pregnancies at term with spontaneous labor (n = 49); (4) PTL and intact membranes who delivered at term (n = 49); (5) PTL without IAI who delivered preterm (n = 26); (6) PTL with IAI (n = 65); (7) preterm PROM without IAI (n = 25); and (8) preterm PROM with IAI (n = 77). Maternal plasma PTX3 concentrations were determined by ELISA. Results. (1) Maternal plasma PTX3 concentrations increased with advancing gestational age (r = 0.62, p < 0.001); (2) women at term with spontaneous labor had a higher median plasma PTX3 concentration than those at term not in labor (8.29 ng/ml vs. 5.98 ng/ml, p = 0.013); (3) patients with an episode of PTL, regardless of the presence or absence of IAI and whether these patients delivered preterm or at term had a higher median plasma PTX3 concentration than normal pregnant women (p < 0.001 for all comparisons); (4) similarly, patients with preterm PROM, with or without IAI had a higher median plasma PTX3 concentration than normal pregnant women (p < 0.001 for both comparisons); and (5) among patients with PTL and those with preterm PROM, IAI was not associated with significant changes in the median maternal plasma PTX3 concentrations. Conclusions. The maternal plasma PTX3 concentration increases with advancing gestational age and is significantly elevated during labor at term and in the presence of spontaneous preterm labor or preterm PROM. These findings could not be explained by the presence of IAI, suggesting that the increased PTX3 concentration is part of the physiologic or pathologic activation of the pro-inflammatory response in the maternal circulation during the process of labor at term or preterm.